<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Î²-2-microglobulin (B2M) is essential for antigen presentation, yet may also possess proto-oncogenic properties </plain></SENT>
<SENT sid="1" pm="."><plain>AIM: To determine the prognostic impact of B2M in patients with mismatch repair (MMR) proficient and deficient <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and to investigate whether this effect on outcome is dependent on the local immune response </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: B2M protein expression and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-infiltrating immune cells (CD3, CD16, CD163, CD20, CD4, CD45RO, CD56, CD68, CD8, FoxP3, GranzymeB, iNOS, mast cell tryptase, MUM1, PD1, <z:hpo ids='HP_0002326'>TIA</z:hpo>-1) were evaluated in a well characterised tissue microarray of 408 CRCs </plain></SENT>
<SENT sid="3" pm="."><plain>The predictive value for clinicopathological features and the prognostic significance of B2M expression were analysed, stratified by MMR status and the immunohistological characteristics of immune cell infiltrates </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Interobserver agreement for B2M staining was high (intra-class correlation coefficient=0.91) </plain></SENT>
<SENT sid="5" pm="."><plain>Complete B2M loss was more frequent in MMR-deficient (19.4%) compared to MMR-proficient (7.1%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (p&lt;0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>In MMR-deficient cases, B2M loss predicted rare local recurrence (p=0.034), infrequent nodal-positivity (p=0.035), absence of distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (p=0.048; sensitivity=100%) and a trend towards favourable survival (p=0.124) independent of immune infiltrates </plain></SENT>
<SENT sid="7" pm="."><plain>No associations between B2M and clinicopathological features were observed in MMR-proficient cases </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our data show for the first time that absence of B2M protein expression identifies MMR-deficient <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> with a favourable clinical course and absence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Validation of B2M protein expression for sub-classification of MMR-deficient <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is recommended for future clinical trials </plain></SENT>
</text></document>